Long-term open-label CP-690,550 safety study in moderate to severe chronic plaque psoriasis

Phase 3, open-label trial of tofacitinib in psoriasis (2 arms), sponsored by Pfizer. Primary endpoints: Incidence and severity of adverse events during treatment, Incidence of clinical laboratory abnormalities and change from baseline in clinical laboratory values and 5 more. Started May 2012; status: recruiting.